Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of seven systematic review(s)/meta-analysis(es). ^[1-7]
• The studies included adults with post-stroke spasticity (PSS) treated with abobotulinumtoxinA (aboBoNT-A) and physiotherapy, showing cost-effectiveness with a quality-adjusted life-year (QALY) gained below €40,000. They also involved children with upper limb spasticity, where aboBoNT-A demonstrated a trend towards higher response rates compared to onabotulinumtoxinA, leading to improved health-related quality of life (HRQoL). Additionally, adults with cervical dystonia showed better tolerance and fewer adverse events with aboBoNT-A compared to the anticholinergic trihexyphenidyl.
• In adults with cervical dystonia, abobotulinumtoxinA was associated with fewer adverse events compared to the anticholinergic drug trihexyphenidyl, which had more reported events such as dry mouth and memory problems. Pediatric patients treated with aboBoNT-A exhibited similar safety outcomes as other botulinum toxin therapies, with no specific adverse events highlighted. Additionally, cosmetic applications of aboBoNT-A reported no serious adverse events, indicating a favorable safety profile in aesthetic treatments.
• The evidence highlights several population types relevant to abobotulinumtoxinA (aboBoNT-A), including adults with post-stroke spasticity, adults with disabling limb spasticity, children with upper limb spasticity, adults with cervical dystonia, and patients seeking cosmetic improvements. Specifically, adults with PSS showed improved outcomes when treated with aboBoNT-A in combination with physiotherapy, while pediatric patients exhibited higher treatment response and improved health-related quality of life compared to onabotulinumtoxinA. Additionally, adults with cervical dystonia tolerated aboBoNT-A better, with fewer adverse events compared to the anticholinergic trihexyphenidyl.